Skip to main content
Top
Published in: Inflammation Research 5/2010

01-05-2010 | Original Research Paper

Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia

Authors: Maria Hatzistilianou, Aleka Rekliti, Fanni Athanassiadou, Dorothea Catriu

Published in: Inflammation Research | Issue 5/2010

Login to get access

Abstract

Objective and design

The aim of this study was to assess the value of procalcitonin (PCT), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1b, IL-8, and soluble TNF receptor II (sTNFRII) in early and rapid diagnosis of infection in neutropenic children with acute lymphoblastic leukemia (ALL) and to distinguish bacterial from viral infections.

Patients

The study included five groups (A, B, C, D, and E) of children with ALL undergoing intensive chemotherapy. Groups A and B consisted of neutropenic children with bacterial and viral infection, respectively. Groups C and D consisted of nonneutropenic children with bacterial and viral infection, respectively. Group E consisted of children without neutropenia and without fever.

Methods

In all groups, blood samples were collected upon admission and then for 7 days on a daily basis. Levels of CRP, PCT, TNF-a, IL-1b, IL-8, and sTNFRII were determined in all blood samples.

Results

We found a highly significant difference in PCT levels between bacterial and nonbacterial episodes. Sensitivity and specificity of PCT were 94 and 96.5%, respectively.

Conclusions

Serial measurement of PCT levels on a daily basis seems to be helpful for early prediction of severe bacterial infections, monitoring febrile episodes regarding response to antibiotic therapy, and early detection of complications in the infectious process.
Literature
1.
go back to reference Finberg RW, Talcott JA. Fever and neutropenia-how to use a new treatment strategy. N Engl J Med. 1999;341(5):362–8.CrossRefPubMed Finberg RW, Talcott JA. Fever and neutropenia-how to use a new treatment strategy. N Engl J Med. 1999;341(5):362–8.CrossRefPubMed
2.
go back to reference Crokaert F. Febrile neutropenia in children. Int J Antimicrob Agent. 2000;16:173–7.CrossRef Crokaert F. Febrile neutropenia in children. Int J Antimicrob Agent. 2000;16:173–7.CrossRef
3.
go back to reference Schimpff SC. Infections in the cancer patients-diagnosis, prevention and treatment. In: Mandell GL, Douglas RG, Bennet JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 2666. Schimpff SC. Infections in the cancer patients-diagnosis, prevention and treatment. In: Mandell GL, Douglas RG, Bennet JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 2666.
4.
go back to reference Laws HJ, Schneider DT, Janssen G, Wessalowski R, Dilloo D, Meisel R, et al. Trends in infections in children with malignant disease in 2000: comparison of data of 1980/81. Pediatr Hematol Oncol. 2000;24(5):343–54.CrossRef Laws HJ, Schneider DT, Janssen G, Wessalowski R, Dilloo D, Meisel R, et al. Trends in infections in children with malignant disease in 2000: comparison of data of 1980/81. Pediatr Hematol Oncol. 2000;24(5):343–54.CrossRef
5.
go back to reference Von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Macrobiol Infect Dis. 2004;23:539–44. Von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Macrobiol Infect Dis. 2004;23:539–44.
6.
go back to reference Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and isozyme levels in serum and peripheral blood lymphocytes in childhood acute lymphoblastic leukemia. Mol Immunol. 1998;35(11–12):754–9.CrossRef Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and isozyme levels in serum and peripheral blood lymphocytes in childhood acute lymphoblastic leukemia. Mol Immunol. 1998;35(11–12):754–9.CrossRef
7.
go back to reference Petrola V, Toikka P, Irjala K, Mertsola J, Ruuskanen O. Discrepancy between total white blood cell count and serum C-reactive protein levels in febrile children. Scand J Infect Dis. 2007;39(6):560–5.CrossRef Petrola V, Toikka P, Irjala K, Mertsola J, Ruuskanen O. Discrepancy between total white blood cell count and serum C-reactive protein levels in febrile children. Scand J Infect Dis. 2007;39(6):560–5.CrossRef
8.
go back to reference Kalio R, Bloigu A, Surcel HM, Syrjiada H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer. 2001;9:124–9.CrossRef Kalio R, Bloigu A, Surcel HM, Syrjiada H. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer. 2001;9:124–9.CrossRef
9.
go back to reference Hartel C, Deutser M, Lehrnbecher T, Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49(6):767–73.CrossRefPubMed Hartel C, Deutser M, Lehrnbecher T, Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49(6):767–73.CrossRefPubMed
10.
go back to reference Sheu JN, Chen MC, Lue KH, Sl Cheng, Lee IC, Chen SM, et al. Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. Cytokine. 2006;36(5–6):276–82.CrossRefPubMed Sheu JN, Chen MC, Lue KH, Sl Cheng, Lee IC, Chen SM, et al. Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. Cytokine. 2006;36(5–6):276–82.CrossRefPubMed
11.
go back to reference Shereen Mohamed EM, Manar Mohamed M, Manar Mohamed I, Lobna M, Hadir A. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29(3):131–6.CrossRef Shereen Mohamed EM, Manar Mohamed M, Manar Mohamed I, Lobna M, Hadir A. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29(3):131–6.CrossRef
12.
go back to reference Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kuel J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414–9.CrossRefPubMed Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kuel J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414–9.CrossRefPubMed
13.
go back to reference Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458–61.CrossRefPubMed Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458–61.CrossRefPubMed
14.
go back to reference Hoffmann G, Schobersberger W. Procalcitonin as a marker. Acta Anaesthesiol Scand. 2003;47(2):237–43.CrossRefPubMed Hoffmann G, Schobersberger W. Procalcitonin as a marker. Acta Anaesthesiol Scand. 2003;47(2):237–43.CrossRefPubMed
15.
go back to reference Gendel D, Bohuon C. Procalcitonin a marker of bacterial infection. Infection. 1997;25:133–8.CrossRef Gendel D, Bohuon C. Procalcitonin a marker of bacterial infection. Infection. 1997;25:133–8.CrossRef
16.
go back to reference Whang KT, Steinwald PM, White JC. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab. 1998;83:3296–301.CrossRefPubMed Whang KT, Steinwald PM, White JC. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab. 1998;83:3296–301.CrossRefPubMed
17.
go back to reference Emporiadou M, Hatzistilianou M, Haidopoulou K, Aggouridaki C, Reklity A, Magnisali C, et al. Procalcitonin and inflammatory cytokines in children with asthma. Eur J Inflamm. 2005;3(2):75–81. Emporiadou M, Hatzistilianou M, Haidopoulou K, Aggouridaki C, Reklity A, Magnisali C, et al. Procalcitonin and inflammatory cytokines in children with asthma. Eur J Inflamm. 2005;3(2):75–81.
18.
go back to reference Bernard L, Ferriere F, Casassus P, Malas E, Leveque S, Guillevin L. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis. 1998;27:914–7.CrossRefPubMed Bernard L, Ferriere F, Casassus P, Malas E, Leveque S, Guillevin L. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis. 1998;27:914–7.CrossRefPubMed
19.
go back to reference Hatzistilianou M, Hitoglou S, Gougoustamou D, Rekliti A, Tzouvelekis G, Nanas C, et al. Serum procalcitonin, adenosine deaminase and its isoenzymes in the aetiological diagnosis of pneumonia in children. Int J Immunopathol Pharmacol. 2002;15(2):119–23.PubMed Hatzistilianou M, Hitoglou S, Gougoustamou D, Rekliti A, Tzouvelekis G, Nanas C, et al. Serum procalcitonin, adenosine deaminase and its isoenzymes in the aetiological diagnosis of pneumonia in children. Int J Immunopathol Pharmacol. 2002;15(2):119–23.PubMed
20.
go back to reference The Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis. 1990;161:397–404. The Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis. 1990;161:397–404.
21.
go back to reference Alexander SW, Pizzo PA. Current considerations in the management of fever and neutropenia. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases. Oxford: Blackwell; 1999. p. 160–80. Alexander SW, Pizzo PA. Current considerations in the management of fever and neutropenia. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases. Oxford: Blackwell; 1999. p. 160–80.
22.
go back to reference Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997;25:551–5.CrossRefPubMed Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997;25:551–5.CrossRefPubMed
23.
go back to reference Penel N, Fournier C, Clisant S, N’Guyen M. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer. 2004;12:593–7.CrossRefPubMed Penel N, Fournier C, Clisant S, N’Guyen M. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer. 2004;12:593–7.CrossRefPubMed
24.
go back to reference Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18:283–8.CrossRefPubMed Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18:283–8.CrossRefPubMed
25.
go back to reference Schuttrump S, Binder L, Hagemann T, Berkovie D, Trumper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98–101. Schuttrump S, Binder L, Hagemann T, Berkovie D, Trumper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98–101.
26.
go back to reference Hitoglou S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki Ch, Athanassiadou F, et al. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukemia. Clin Exp Med. 2005;5:60–5.CrossRef Hitoglou S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki Ch, Athanassiadou F, et al. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukemia. Clin Exp Med. 2005;5:60–5.CrossRef
27.
go back to reference Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–5.CrossRefPubMed Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–5.CrossRefPubMed
28.
go back to reference Hatzistilianou M, Rekleity A, Athanassiadou F, Delutils MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):75–85. Hatzistilianou M, Rekleity A, Athanassiadou F, Delutils MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):75–85.
29.
go back to reference Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta. 2005;351(1–2):17–21.CrossRefPubMed Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta. 2005;351(1–2):17–21.CrossRefPubMed
30.
go back to reference Chesney J, Metz C, Stavitsky AB, Bacher M, Bacher R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998;160:419–25.PubMed Chesney J, Metz C, Stavitsky AB, Bacher M, Bacher R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998;160:419–25.PubMed
31.
go back to reference Harbarth S, Holechova K, Froidevaux C, Pittet D, Ricou B, Grau G, et al. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically III patients admitted with suspected sepsis. J Resp Crit Care Med. 2001;164(3):396–402. Harbarth S, Holechova K, Froidevaux C, Pittet D, Ricou B, Grau G, et al. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically III patients admitted with suspected sepsis. J Resp Crit Care Med. 2001;164(3):396–402.
32.
go back to reference Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble necrosis factor receptor II. Br J Haematol. 2000;111:1093–102.CrossRefPubMed Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble necrosis factor receptor II. Br J Haematol. 2000;111:1093–102.CrossRefPubMed
Metadata
Title
Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia
Authors
Maria Hatzistilianou
Aleka Rekliti
Fanni Athanassiadou
Dorothea Catriu
Publication date
01-05-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 5/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0100-0

Other articles of this Issue 5/2010

Inflammation Research 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.